malaria parasite tyrosyl-trna synthetase secretion ... › bitstream › 1885 › 5217… · tarun...

ARTICLE

�nATuRE CommunICATIons | 2:530 | DoI: 10.1038/ncomms1522 | www.nature.com/naturecommunications

© 2011 Macmillan Publishers Limited. All rights reserved.

Received 7 Apr 2011 | Accepted 29 sep 2011 | Published 8 nov 2011 DOI: 10.1038/ncomms1522

malaria infection triggers pro-inflammatory responses in humans that are detrimental to host health. Parasite-induced enhancement in cytokine levels correlate with malaria-associated pathologies. Here we show that parasite tyrosyl-tRnA synthetase (PfTyrRs), a housekeeping protein translation enzyme, induces pro-inflammatory responses from host immune cells. PfTyrRs exits from the parasite cytoplasm into the infected red blood cell (iRBC) cytoplasm, from where it is released into the extracellular medium on iRBC lysis. using its ELR peptide motif, PfTyrRs specifically binds to and internalizes into host macrophages, leading to enhanced secretion of the pro-inflammatory cytokines TnF-α and IL-6. PfTyrRs-macrophage interaction also augments expression of adherence-linked host endothelial receptors ICAm-1 and VCAm-1. our description of PfTyrRs as a parasite-secreted protein that triggers pro-inflammatory host responses, along with its atomic resolution crystal structure in complex with tyrosyl-adenylate, provides a novel platform for targeting PfTyrRs in anti-parasitic strategies.

1 Structural and Computational Biology Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Road, New Delhi 110 067, India. 2 Immunology Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Road, New Delhi 110 067, India. 3 Institute for Research in Biomedicine (IRB), C/ Baldiri Reixac 15-21, 08028 Barcelona, Catalonia, Spain. 4 Catalan Institution for Research and Advanced Studies (ICREA), Passeig Lluís Companys 23, 08010 Barcelona, Catalonia, Spain. 5 Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK. 6 Department of Biochemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne Victoria 3086, Australia. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to A.S. (email: [email protected]).

malaria parasite tyrosyl-tRnA synthetase secretion triggers pro-inflammatory responsesTarun Kumar Bhatt1,*, sameena Khan1,*, Ved Prakash Dwivedi2, mudassir meraj Banday1, Arvind sharma1, Anmol Chandele1, noelia Camacho3, Lluís Ribas de Pouplana4, Yang Wu5, Alister G. Craig5, Antti Tapani mikkonen6, Alexander Gerd maier6, manickam Yogavel1 & Amit sharma1

ARTICLE

��

nATuRE CommunICATIons | DoI: 10.1038/ncomms1522

nATuRE CommunICATIons | 2:530 | DoI: 10.1038/ncomms1522 | www.nature.com/naturecommunications


Aminoacyl-tRNA synthetases are ancient enzymes responsible for genetic code translation1. These ubiquitous enzymes attach amino acids onto cognate transfer RNAs during pro-

tein translation, and are divided into two classes based on their structural topology1,2. Class I synthetases, like tyrosyl-tRNA syn-thetase (TyrRS), are characterized by a Rossmann fold, and this class contains two conserved ATP-binding motifs (HIGH and KMSKS)3,4. Apart from their parent aminoacylation activity, several aminoacyl-tRNA synthetases perform non-canonical functions in transcriptional regulation, apoptosis, ribosomal RNA biogenesis, angiogenesis and cell signalling5–8. Human TyrRS is processed by an elastase enzyme yielding an amino-terminal TyrRS (also known as mini-TyrRS) and carboxy-terminal EMAPII-like domain9–13. The latter contains cell signalling activity whereas human mini-TyrRS mimics interleukin-8 (IL-8) to chemo-attract polymorphonuclear cells9–13. Human mini-TyrRS interacts with CXCR1/2 receptors and acts as an angiogenic cytokine using a motif called ELR (Glu-Leu-Arg) that it shares with IL-8 (Fig. 1a). For the human mini-TyrRS ELR motif to be functional, the intact human enzyme is required to undergo proteolytic cleavage, which results in the release of EMA-PII domain and subsequent exposure of the ELR motif 9–13.

Plasmodium parasites are the causative agents of malaria. It is estimated that > 300 million clinical malaria cases occur annually, resulting in > 1 million deaths14. Malaria-related deaths occur owing to a range of syndromes including acute anemia and/or cerebral/placental malaria14,15. Most malaria pathology results from an acute inflammatory spurt, followed by activation of the host immune system and dysregulated cytokine release14–18. Human patient studies and mouse malaria models have consistently suggested that infec-tion by the malaria parasite triggers an increase in the levels of numerous pro-inflammatory agents including tumour necrosis factor (TNF-α), interferon gamma (IFN-γ) and interleukin 6 (IL-6) in blood plasma19–21. Although pro-inflammatory cytokines have a major role in patho-physiology of malaria disease16–21, the molecular mechanisms of cytokine release from immune cells remains largely unclear. Until now, several parasite-derived molecular agents have been implicated in triggering cytokine release22–25, but parasite-secreted protein(s) that potentially trigger specific cytokine secre-tion from host immune cells are less well understood. It is critical to understand the pathways and mechanisms that lead to cytokine release in malaria as disease pathology, directly or indirectly, gen-erally results from dysregulation of circulating TNF-α and IL-6 amounts22–25.

Plasmodium falciparum genome contains two copies of tyrosyl-tRNA synthetase-tyrosyl-tRNA synthetase 1 (hereafter PfTyrRS, Plasmodb ID = MAL8p1.125) and tyrosyl-tRNA synthetase 2 (here-after PfTyrRSapi, Plasmodb ID = PF11_0181). PfTyrRS was predicted to be cytoplasmic whereas PfTyrRSapi is probably targeted to the parasite apicoplast6. Here we have investigated the structural, immu-nological and spatial localization attributes of PfTyrRS. Our com-prehensive analyses provide a platform for focusing on PfTyrRS as a new target for development of novel malaria intervention strategies.

ResultsPfTyrRS characterization and structure. Bacterially overexpressed PfTyrRS was purified to homogeneity using affinity and gel-filtration chromatography, and the protein migrates as a dimer (Fig. 1b). PfTyrRS enzyme activity was confirmed using tRNAs obtained by in vitro transcription using T7 RNA polymerase (Fig. 1c)26–28. We determined the three-dimensional structure of PfTyrRS in complex with YAP (tyrosyl-adenylate) to a resolution of 2.2 Å (Fig. 2a,b; Table 1). The crystallographic asymmetric unit contains a canonical tyrosyl-tRNA synthetase dimer. Eighteen N-terminal and three C-terminal residues were not clearly defined in the electron density for each monomer. The overall fold of PfTyrRS is typical of class I synthetases3,4 and comprises a catalytic domain (residues 18–260,

Rossmann fold) and an anti-codon-binding domain (residues 261–370). Human mitochondrial and malaria parasite apicoplastic TyrRS belong to bacterial lineage, whereas human cytoplasmic TyrRS and PfTyrRS belong to a separate eukaryotic group6,29 (Fig. 2c). Structural superposition of 292 Cα atoms between PfTyrRS and human mini-TyrRS (Protein Data Bank, accession code 1N3 L) gives an RMSD of ~1.9 Å (sequence identity ~30%), whereas the RMSD between 144 Cα atoms of PfTyrRS and mitochondrial HsTyrRS (PDB: 2PID) is ~2.5 Å (sequence identity < 10%). In PfTyrRS, the solvent accessible buried surface area at dimer interface is ~1,337 Å2, and its value is comparable with l-Tyr bound mini-HsTyrRS (1,380 Å2) but not with the unliganded mini-HsTyrRS (buried area of 1,531 Å2). In mini-HsTyrRS structure13, the adenosine binding pocket is empty and seems enlarged by

Catalytic domainAnticodon-binding

domain

ELR

Pf TyrRS

HsTyrRS

Mini TyrRS EMAP II domain

ELR

NYR

ScTyrRS

700

800

500

600

200

300

400

100

0

Abs

orba

nce

(mA

U)

BSAdimer132 kDa–200

–100

7.0 8.0 9.0 10.0 11.0 12.0 14.0 15.0

BSAmonomer66 kDa

Elution volume (ml)

20 Pf TyrRS + Plasmodium tRNATyr

10

15

5

00

Am

inoa

cyla

ted

tRN

AT

yr (

pmol

)

Time (min)

13.0 16.0

5 10 15 20

Figure 1 | Tyrosyl tRNA synthetase domain organization and enzyme characterization. (a) Domain organization of TyrRs from P. falciparum, human and yeast. The 21 residue n-terminal extension in PfTyrRs is shown in orange. The ELR motif is shown in red and in yeast TyrRs it is replaced by nYR. (b) Gel filtration curves show both wild-type PfTyrRs (solid blue line) and ELR/AAA mutant (dotted red line) proteins as dimers in solution. (c) Aminoacylation curves with (blue line) and without (red line) added native PfTyrRs and using Pf-tRnATyr.

ARTICLE

�




~3 Å on either side of the binding pocket whereas, in YSA (5′-O- [N-(l-Tyrosyl) sulfamoyl] adenosine)-bound mitochondrial HsTyrRS29 and in YAP-bound PfTyrRS, the adenosine-binding pocket is tighter (Fig. 2d). In PfTyrRS, the key synthetase motif of KMSKS loop is highly ordered and close to the bound substrate at the active site, whereas, in both cytoplasmic and mitochondrial HsTyrRS, this is found to be disordered (Fig. 2d). We find several other key structural differences between mini-HsTyrRS and PfTyrRS (Fig. 2c,d). First, at the primary sequence level, PfTyrRS has an N-terminal 21 residue extension whose role is unclear (Fig. 1a). On the other hand, human cytoplasmic TyrRS has a C-terminal extension in the form of an EMAPII domain that undergoes proteolytic processing to reveal a host module more similar in size to PfTyrRS9–13 (Fig. 1a). The most notable and intriguing feature of both the mini-HsTyrRS and PfTyrRS is presence of an ELR motif (Figs. 1a and 2e). This tri-peptide signature is present in, among others, cytokines like IL-8 (refs 9–13,30). As shown in Figure

2e, ELR motifs decorate the surfaces of IL-8, mini-HsTyrRS and PfTyrRS. Structural alignment of ELR motifs from these three reveals striking conformational conservation (RMSD < 1 Å). In PfTyrRS, the ELR motif resides on α-helix 2 whereas, in mini-HsTyrRS, it is located at α-helix 5 (Fig. 2e). In both PfTyrRS and mini-HsTyrRS, the ELR motif is significantly distal from aminoacylation sites (Fig. 2e). In full-length cytoplasmic HsTyrRS, the ELR motif is buried under the C-terminal EMAPII domain, and this motif is exposed after proteolytic cleavage9–13. In contrast, the PfTyrRS ELR motif is exposed in three-dimensional space and does not require processing for its surface display. Therefore, in the parasite enzyme the ELR tri-peptide is continually solvent accessible owing to its presence in a different part of the overall three-dimensional structure relative to human TyrRS (Fig. 2a,e). Subtle structural perturbations caused by single residue mutations near the ELR motif can activate procytokine activity of human TyrRS11. These data on human TyrRS11 suggested that the twin attributes of cytokine trigger and

ELRYAP

KMSKSHIAQ

Cys89 Cys89

Trp98Trp98

L-TyrYAP YSA

HIAQ

KMSKS

KMSSSKLGKS

HAVYHVGH

Cytoplasmic mini-HsTyrRS Mitochondrial HsTyrRSPf TyrRS

Pf : ELRHs : ELR Arg

IL8: ELR

Glu

ELR

Pf : ELRHs : ELR

Leu

a

d

e

b c

Figure 2 | Crystal structure of PfTyrRS. (a) PfTyrRs:Tyr-AmP (YAP) complex structure where the ELR, KmsKs and HIGH motifs are shown in red, yellow and orange, respectively. Bound YAP is shown in stick model (green). (b) stereoview of the experimental electron density map (2|Fo|-|Fc|) for a portion of the final atomic model. The map is contoured at 1.2 σ level. (c) sequence alignment between mini-HsTyrRs and PfTyrRs. Important motifs are highlighted in red boxes and the ELR motifs are marked. (d) A close-up view of KmsKs loop and active site region of PfTyrRs along with corresponding regions from cytoplasmic mini-HsTyrRs and mitochondrial HsTyrRs (with 5′-o-[n-(l-Tyrosyl) sulfamoyl] adenosine also known as YsA). The disordered KmsKs loop is shown as dotted lines in human structures and the bound substrate/analog is shown as sticks. (e) structural alignment and ELR motifs in mini-HsTyrRs (purple), PfTyrRs (green) and HsIL-8 (orange).

ARTICLE

��




aminoacylation can coexist in a tyrosyl-tRNA synthetase11. Indeed, our description of the parasite PfTyrRS provides an excellent natural example of a synthetase enzyme with constitutively active ELR motif (Fig. 2). Interestingly, the ELR motif is absent in TyrRSs from lower eukaryotes and prokaryotes (Fig. 1a), again suggesting that ELR motif is independent of the parent aminoacylation activity of these enzymes.

Structural comparisons suggest sequence differences in 11 key residues that contribute to l-Tyr binding (5 residues) and adeno-sine binding (6 residues) between human and parasite enzymes (Fig. 2c,d). Residues in the conserved HIGH and KMSKS motifs are different between PfTyrRS (HIAQ and KMSKS) and mini-HsTyrRS (HAVY and KMSSS). In the l-Tyr bound mini-HsTyrRS, a K + ion is bound near adenine binding pocket whereas this space is empty in unliganded state of mini-HsTyrRS. In PfTyrRS, there is no density for an ion like K + , and further the residues involved in K + ion coordination in mini-HsTyrRS are not conserved in PfTyrRS. Therefore, several subtle yet crucial differences between host and pathogen tyrosyl-tRNA synthetase active sites (Fig. 2b–d) present a window for exploiting the malaria parasite enzyme for structure-based inhibitor discovery—consistent with recent high-throughput chemical library screening data31.

Parasite and erythrocyte localization of PfTyrRS. Confocal microscopy was performed using protein-A purified IgG fraction of rabbit antibodies that were raised against recombinant PfTyrRS. Our localization data show that PfTyrRS is present in all three stages of asexual parasite life cycle: rings, trophozoites and schi-zonts (Fig. 3a; Supplementary Movies 1, 2 and 3 based on z-stacked confocal analyses of rings, trophozoites and schizonts, respec-tively—DAPI is in blue and PfTyrRS in green). Closer examination of PfTyrRS localization in infected erythrocytes during tropho-zoite and schizont stages revealed possible secretion of PfTyrRS into infected red blood cell (iRBC), despite absence of an export

signal in PfTyrRS sequence (Fig. 3a). Similar results were obtained using PfTyrRS-GFP fusion parasite transgenic cell lines (Fig. 3b). We therefore tested whether secretion of PfTyrRS occurred from schizonts at time of iRBC rupture. To address this, culture super-natants of infected RBCs were separated on SDS–PAGE, and west-ern blotting was performed using anti-PfTyrRS antisera (Fig. 3c). This experiment indicated a band of ~42 kDa in iRBC medium that corresponds to the molecular size of PfTyrRS. As controls, the para-site-secreted MSP1 and non-secreted proteins like DTD32,33 and fal-cipain 2 were also used (Fig. 3c). We also performed western blot analysis using anti-GFP antibody on PfTyrRS-GFP parasite cell line supernatants. PfTyrRS-GFP fusion protein band of expected molec-ular weight (70 kDa) was clearly seen in iRBCs supernatants but not in supernatants from uninfected RBCs controls (Fig. 3d). These experiments suggest that PfTyrRS is expressed in all asexual para-site stages, and that it is exported to the host erythrocyte cytosol, from where it is released into blood plasma on iRBC rupture.

PfTyrRS interaction with host immune cells. Release of PfTyrRS from iRBCs and the presence of an exposed and conformationally competent ELR motif persuaded us to address directly the binding of TyrRS to host immune cells. We performed an in vivo experi-ment where mice were infected with Plasmodium yoelii (XNL). Subsequently, spleen cells containing peripheral blood mono-nuclear cells (PBMCs) were isolated from these infected mice and then presence of native TyrRS was tested using anti-TyrRS-specific antibodies by flow cytometry (Fig. 4a). We observed specific TyrRS binding to mouse macrophages and dendritic cells, among others (Fig. 4a). A corresponding in vitro experiment using human PBMCs also showed specific interaction of PfTyrRS with human macrophages and, to a lesser degree, with dendritic cells (Fig. 4b). To validate these observations further, we assessed binding of PfTyrRS to mouse and human immune cells using confocal microscopy (Fig. 4c,d). We detected both binding and internali-

Table 1 | Data collection and refinement statistics.

Parameters PfTyrRS-YAP

Data collection space group C2 unit cell dimensions a, b, c (Å) 137.5, 46.5, 141.3 α, β, γ (°) 90, 93.8, 90 Resolution (Å) 50.0–2.2 Rmerge 0.056 (0.405) I/σ(I) 51.0 (4.8) Completeness (%) 94.7 (82.2) Redundancy 14.1 (9.8)

Refinement Resolution (Å) 50.0–2.2 no. of reflections 42,842 Rwork/Rfree 0.172/0.214

No. of atoms Protein (two molecules) 5,726 Ligand/waters 70/371

B-factors (Å2) Protein 57 Ligand/waters 39/61

R.m.s. deviations Bond lengths (Å) 0.007 Bond angles (°) 1.09

Values in parentheses are for highest-resolution shell.

DAPI

Pre-imm

Ring

Troph

Schizo

DAPI

Ring

Troph

Schizo

Culturesupernatant

Pf-celllysate

Pf TyrRS 42 kDa

Pf DTD

Pf MSP1

19 kDa

19 kDa

Pf falcipain2 28 kDa

iRBCSup

RBCSup

70 kDaPf TyrRS-GFP

Anti-GFP

Mer

ge w

ith

phas

e

Mer

ge

PfTyr

RS-Ab

Mergewith

phaseMergeGFP-Ab

Figure 3 | Cellular localization of PfTyrRS. (a) Confocal microscopy of P. falciparum asexual stages—rings, trophozoites and schizonts using anti-sera raised in rabbits against PfTyrRs. scale bar in red corresponds to a size of 5 µm (b) Confocal microscopy using anti-GFP antibody (green) in PfTyrRs-GFP transgenic parasite cell lines. Parasite nucleus was stained with DAPI (blue) in each case. scale bar in red corresponds to a size of 5 µm. (c) Enhanced chemi-luminiscence of parasite culture supernatants using antibodies against PfTyrRs, PfDTD, PfmsP1 and Pf falcipain 2 and (d) Enhanced chemi-luminiscence of parasite culture supernatants using anti-GFP antibody.

ARTICLE

�




zation of PfTyrRS by host macrophages. Supplementary Movie 4 is based on Z-stacking of these confocal images where macro-phages are stained for nucleus (DAPI, blue) and for PfTyrRS (in

green). These data led us to hypothesize an ELR-motif-mediated interaction of P. falciparum tyrosyl-tRNA synthetase with human macrophages (Fig. 4c,d).

DAPI

No TyrRS +anti-His

TyrRS +anti-His

TyrRS +anti-TyrRS

DAPI Anti-His Ab Anti-TyrRS Ab Phase

DAPI Pf TyrRS-Ab Merge

TyrRSwild type

TyrRS ELR/AAA

Pre-immune

No addedTyrRS

Uninfected UninfectedInfected Infected OverlayF

4/80

CD

11c

Tyr

RS

Gr1

Ope

nO

pen

CD

19

Ope

nC

D11

cO

pen

Ope

nO

pen

Tyr

RS

Tyr

RS

Tyr

RS

Tyr

RS

Tyr

RS

CD11b

CD11b

CD11b

CD11c

CD11b

MHCII

Mac

roph

ages

Mac

roph

ages

Gating No protein +TyrRs Overlay

Den

driti

cce

lls

HLA-DR

CD14

CD4

CD8

CD19

CD

4 T

cel

lsC

D8

T c

ells

B c

ells

cDC

sN

eutr

ophi

lsC

D4

T c

ells

CD

8 T

cel

lsB

cel

ls

B220 B220

CD8

CD4 CD4

CD8

MergeAntibody Merge with phase

9% 1% 0%

0%

0%

1%

43% 21% 69%

11%0.1%

<1% <1%

<1%

<1%<1%

<1%

53%

5%

8%

39%1%

77% 96%

1%

7%

18% 4%

8% 5%

3%39%

1%

0.15%

Figure 4 | TyrRS interaction with PBMCs in vivo and in vitro. (a) FACs-based binding of mouse PBmCs with anti-PfTyrRs antibodies in an ex vivo experiment. Left panel shows gating; middle panel shows TyrRs binding in immune cells tested in both uninfected and infected mice. overlay histograms are derived from the TyrRs expression dot plots wherein solid grey histogram is uninfected and the black bold line represents data for infected mice. Data are cumulative of two independent experiments. (b) Binding of PfTyrRs to human PBmCs showing specific interaction with human macrophages and dendritic cells. Left panel shows gating; middle panel shows PfTyrRs binding to various immune cells. The overlay histogram is derived from PfTyrRs-binding dot plots wherein solid grey histogram is without PfTyrRs and black solid line is with PfTyrRs. Confocal images of binding and internalization of PfTyrRs into (c) mouse dendritic cells (top panel), mouse macrophages (bottom panel) and (d) human macrophages. In (d) along with wild-type PfTyrRs (green), the controls of pre-immune sera, ELR/AAA mutant PfTyrRs, and primary/secondary antibodies alone (that is, no added PfTyrRs) are shown. For nucleus visualization, DAPI (blue) localization is also shown. The red scale bar in confocal images corresponds to a size of 15 µm.

ARTICLE

��




Triggering of cytokine secretion by PfTyrRS. Our observations on interaction of PfTyrRS with host immune cells prompted us to test whether the ELR motif present in PfTyrRS could enable it to trigger release of cytokines from macrophages. We tested this hypothesis by incubating mouse and human macrophage cell lines with recom-binant wild-type PfTyrRS, with a mutant ELR/AAA-PfTyrRS, with lipopolysaccharide (LPS) (as positive control), with media alone and PfDTD (last two as negative controls). In these studies, the amounts of PfTyrRS used were in nanomolar (nM) concentration ranges, similar to amounts used in studies with human mini-TyrRS9–13. Time kinetic analysis using ELISA revealed maximal production of the inflammatory cytokines TNF-α, IL-6 and IL-1(α and β) within 6 hours of culture (Tukey’s test—P < 0.001) (Fig. 5a,b), but not of IL-10 or IL-12 (Fig. 5c). The cytokine release mediated by PfTyrRS

was dose-dependent, and occurred as early as 4 hours post-incu-bation of macrophages with PfTyrRS (Fig. 5d). Interestingly, the mutant PfTyrRS (where ELR was replaced with AAA sequence) did not trigger cytokine release from macrophages and behaved similar to the control proteins PfDTD32,33 or PfSerRS. In all experi-ments, LPS was used as a positive control, and all proteins used in these experiments were confirmed to be endotoxin free (Methods). We also observed that PfTyrRS that had been immunoprecipitated from parasite culture supernatants was equally capable of trigger-ing release of TNF-α and IL-6 from human macrophage ThP1 cell lines (Fig. 5e). Finally, pre-incubation of PfTyrRS with anti-PfTyrRS antibodies substantially blocked TNF-α (Tukey’s test—P < 0.05) and IL-6 production (Tukey’s test—P < 0.01) from human macrophages (Fig. 5e), suggesting specific, motif-based PfTyrRS interaction with human macrophages.

Potential receptor(s) for PfTyrRS on human macrophages. To identify a receptor for PfTyrRS on macrophages, we pre-incubated human macrophages with anti-CXCR1/2 and anti-PfTyrRS anti-bodies, and tested whether antibody-mediated receptor or protein blockades inhibited PfTyrRS-macrophage interaction (Fig. 6a). Specific antibody-mediated blocking of CXCR2 receptor (Tukey’s test—P < 0.05), but not the CXCR1 receptor, on human macro-phages reduced PfTyrRS binding by ~twofold (Fig. 6a). Blocking of PfTyrRS with anti-PfTyrRS antibodies also reduced binding of the protein to macrophages (Tukey’s test—P < 0.05) (Fig. 6a). Further-more, blockage of PfTyrRS-macrophage interactions using either anti-CXCR2 or anti-PfTyrRS antibodies also significantly reduced the release of TNF-α (Tukey’s test—P < 0.05) and IL-6 (Tukey’s test—P < 0.001) from human macrophages (Fig. 6b). To further probe the significance of ELR motif in binding of PfTyrRS to macrophages, we tested inhibition of PfTyrRS-macrophage interaction using peptides in which the wild-type PfTyrRS ELR peptide sequence (DELRV) was mutated residue-wise to DELAV, DAAAV and DELKL. Fluo-rescence-activated cell sorting (FACS)-based binding studies of PfTyrRS in presence of 100 nM of these peptides showed a signifi-cant reduction in binding with only the DELRV peptide sequence (Fig. 6c). The DELKL peptide was less competent in competing whereas the other two peptides did not compete at all (Fig. 6c). Additionally, the PfTyrRS-triggered release of TNF-α and IL-6 from human macrophages was significantly reduced in presence of

400

300 6 h24 h

P<0.001 P<0.001

20048 h

100

a

b

c

d

e

TN

F-α

pg

ml–1

TN

F-α

pg

ml–1

0

Med

ia

10,000 P<0.001P<0.001

8,000

6 h

24 h48 h

6,000

4,000

IL-6

pg

ml–1

2,000

0

ELR/A

AA

4,000P<0.001 P<0.001

3,0003,500 6 h

24 h

2,0002,500 48 h

1,0001,500

IL-6

pg

ml–1

5000

Med

ia

P<0.001 P<0.001

1,2001,400

8001,000 6 h

24 h48 h

400600

2000

Med

ia

100nm

TyrRS

1 nm T

yrRS

10nm

Tyr

RS

100 nm

Tyr

RS

ELR/A

AADTD

Med

iaLP

S

LPS+1

00nM

TyrRS

1nm T

yrRS

10nm

Tyr

RS

100nm

Tyr

RS

ELR/A

AADTD

Med

iaLP

S

LPS+1

00nM

TyrRS

DTD

ELR/A

AAM

edia

LPS

LPS+1

00nM

TyrRS

400 P<0.001

300IL-1αIL-1βP<0.001

pg m

l–1

200IL-10IL-12

100

0

2,500

2,000 P<0.001

P<0.001

1,500

1,000

TN

F-α

pg

ml–1

TN

F-α

pg

ml–1

0

500

5,000 P<0.001P<0.001

4,000

3,000

IL-6

pg

ml–1

IL-6

pg

ml–1

2,000

0

1,000

P<0.052,000 P<0.05P<0.05

1,500

1,000

500

0

4,000P<0.01 P<0.001

3,000

2,000

1,000

0

ELR/A

AA

100m

M

DTD10

0mM

TyrRS LP

SLP

SM

edia

DTD

TyrRS

ELR/A

AA

PfTyr

RS

PfSer

RS

ELR/A

AA

PfTyr

RS

PfSer

RS

Sup

Sup+αTyr

RS

TyrRS

PD-Tyr

RS+αTyrRS

PD-Tyr

RSSup

Sup+αTyr

RS

TyrRS

PD-Tyr

RS+αTyrRS

PD-Tyr

RS

P<0.001

Figure 5 | Effect of PfTyrRS on mouse macrophages. (a) Cytokines levels were measured using BioPlex kit (Bio-Rad) and the secretion profiles of TnF-α and IL-6 using mouse macrophages were measured at different time points. media alone, PfDTD/PfserRs enzymes and ELR-AAA mutant of PfTyrRs were used as negative controls. LPs was used as positive control in all experiments. (b) Identical experiment as in (a) except that the human macrophage cell line ThP1 was used. This experiment has the extra negative control of PfserRs. (c) secretion profiles of extra cytokines (IL-1, IL-10 and IL-12) that are secreted from human macrophages on exposure to PfTyrRs. (d) Dose-dependent increase in secretion of TnF-α and IL-6 when increasing concentrations of PfTyrRs were used with human macrophages. (e) Cytokine secretion profiles using P. falciparum culture supernatants alone (sup), supernatants incubated with anti-TyrRs antibody (sup + αTyrRs), parasite culture supernantant-immunoprecipitated PfTyrRs (PD-TyrRs) and finally parasite culture supernantant -immunoprecipitated PfTyrRs with its antibody (PD-TyrRs + αTyrRs). TnF-α and IL-6 secretion is clearly enhanced significantly when immunoprecipitated PfTyrRs (PD-TyrRs) is used. Triggering activity of PfTyrRs (PD-TyrRs) is blocked when pre-incubated with anti-PfTyrRs antibodies, indicating specific activation of macrophages with native PfTyrRs (PD-TyrRs). Experiments were repeated three times and error bars indicate standard deviation. Tukey’s test was performed and P-values are shown such that the end points of the lines below P-value represent the datasets that were compared.

ARTICLE

�




DELRV peptide (Tukey’s test—P < 0.05) (Fig. 6d). These data, along with our observation that the ‘ELR/AAA’ PfTyrRS mutant does not bind to human macrophage cells (Fig. 4c,d), strongly highlight a role for ELR motif in PfTyrRS interactions with human macrophages. We therefore conclude that ELR-motif-based PfTyrRS binding likely

occurs using specific receptors on human macrophages, and that this binding leads to very specific host immune system activation.

PfTyrRS-stimulated macrophage upregulate ICAM-1 and VCAM-1. P. falciparum cytoadherence enables parasite seques-

100

TyrRS aloneTyrRS

+anti-CXCR1TyrRS

+anti-CXCR2TyrRS

+anti-CXCR1+2TyrRS

+anti-TyrRS(1:10)

33.3%±4.2% 30.8%±0.6% 19.8%±5.5% 24.7%±6.3% 23.9%±2.0%

20

40

60

80

100 101 102 1030

104 100 101 102 103 104 100 101 102 103 104 100 101 102 103 104 100 101 102 103 104

100 101 102 103 104 100 101 102 103 104 100 101 102 103 104 100 101 102 103 104 100 101 102 103 104

Cou

nts

TyrRS intensity

2,000

a

b

c

d

P<0.05 P<0.05

1,500

1,000

500TN

F-α

pg

ml–1

0

TyrRS+αTyrR

S

TyrRS

TyrRS+DELRV

TyrRS+DELAV

TyrRS+DAAAV

TyrRS+DELKL

TyrRS

TyrRS+DELRL

TyrRS+DELAV

TyrRS+DAAAV

TyrRS+DELKL

4,000P<0.001 P<0.001

3,000

2,000

IL-6

pg

ml–1

1,000

0

TyrRS alone TyrRS +DELRV TyrRS +DELKL TyrRS +DELAV TyrRS +DAAAV

40

60

80

10041.9%±3.9%

0

20

TyrRS intensity

Cou

nts

2,000 P<0.05

1,500

1,000

TN

F-α

pg

ml–1

500

0

4,000P<0.001

3,000

2,000

IL-6

pg

ml–1

1,000

0

TyrRS

TyrRS+αCXCR2

TyrRS+αCXCR1

TyrRS+αTyrR

STyrR

S

TyrRS+αCXCR2

TyrRS+αCXCR1

33.3%±4.2% 6.9%±4.7% 38.7%±3.1% 35.8%±7.0%

Figure 6 | Potential PfTyrRS receptor on human macrophages. (a) FACs analysis of PfTyrRs binding to human macrophages. PfTyrRs binding to macrophages is reduced when macrophages had been pre-incubated anti-CXCR2 or with anti-PfTyrRs antibodies. Binding was not reduced significantly with anti-CXCR1 antibodies. overlay histograms show binding of PfTyrRs to the surface of human macrophages (black line) with unstained controls (grey solid) as background. (b) Cytokine secretion assays for TnF-α and IL-6 using human macrophages and anti-CXCR1, anti-CXCR2 and anti-PfTyrRs antibodies. secretion of these pro-inflammatory cytokines is reduced when anti-CXCR2 and anti-PfTyrRs antibodies were pre-incubated with human macrophages. (c) FACs analysis of PfTyrRs binding to human macrophages using four different ELR-mutant peptides in competition assays. overlay histograms show PfTyrRs surface staining (black line) with unstained control (grey solid) as background. (d) Cytokine secretion assays for TnF-α and IL-6 using human macrophages and various ELR-mutant peptides. no significant difference was observed for mutant peptides in these assays. Experiments were repeated three times and the error bars indicate the standard deviation. Tukey’s test was performed and P-values are shown such that the end points of the lines below P-value represent the datasets that were compared.

ARTICLE

��




tration in host tissues, allowing these parasites to avoid splenic clearance which involves degradation and clearing of infected RBCs by the spleen34–40. In severe malaria episodes, an increase in the levels of TNF-α is coupled with enhanced expression of endothelial cell receptors such as ICAM-1 (intercellular adhesion molecule-1), VCAM-1 (vascular cell adhesion molecule-1) and E-selectin34–40. We therefore tested whether recombinant PfTyrRS could modulate expression of endothelial receptors in a static cytoadhesion model assay system. For this ‘triggering’ to work, PfTyrRS had to first initiate enhanced secretion of cytokines like TNF-α from macrophages, and then the increased levels of secreted cytokines would have to induce overexpression of endothelial receptors like ICAM-1 and VCAM-1. As our experimental data show, this is indeed what PfTyrRS was able to achieve (Fig. 7). When HUVECs (primary human umbilical vein endothelial cells) were co-cultured with culture supernatants of PfTyrRS-activated macrophages, we found strong upregulation of both ICAM-1 and VCAM-1 receptors (Tukey’s test—P < 0.05) (Fig. 7a). A PfTyrRS-induced dose-dependent increase in expression of ICAM-1 was also evident (Fig. 7b). These effects were not due to cell toxicity of PfTyrRS on HUVECs (Fig. 7c). These experiments therefore provide fundamental molecular insights and also a tool to dissect the molecular basis of cytoadherence using PfTyrRS as a ‘trigger’. Increased levels of circulating cytokines in malaria infected individuals may activate the host immune system to check or con-trol very high parasitemia levels, which may prove lethal both to pathogen and host.

DiscussionOne of the key pathogenic mechanisms in the virulence of P. falciparum is the phenomenon of cytoadherence, attributed to increased adhesion of infected erythrocytes to blood capillaries34–42. In particular, cerebral and placental malaria seem to be dependent on crucial protein–protein interactions that occur between a para-site virulence factors and the endothelial/placental receptors34–42. The host immune system is hijacked by parasite-derived factors to assist in cytoadherence, for example, by cytokine-induced increased expression of a range of adhesion molecules16,18–25. Numerous field reports on human malaria and mouse model studies have shown that malaria infection alters host cytokine profiles by modulating dendritic cells and macrophages16,18–25. This is presumably done to aid in parasite survival and transmission. Elevated cytokine levels have a variety of physiological effects, generally to the detriment of the hosts16,34–42. In fact, malaria as a disease has been looked up on as a manifestation of enhanced pro-inflammatory cytokine produc-tion in host16,34–42. For example, the clinical manifestations of severe malaria can be correlated with induction of strong pro-inflammatory responses in which plasma levels of circulating TNF-α, IFN-γ and IL-6 increase significantly19–21. Pathways that propel host immune cell activation in malaria remain mysterious in context of parasite-derived protein antigens. The interaction of latter with macrophages and dendritic cells must occur before cytokine induction. So far, studies have identified several such molecular agents2–22, but, to our knowledge, no parasite-secreted housekeeping enzyme has been attri-buted with the ability to trigger enhanced secretion of cytokines like TNF-α and IL-6. In this context, we find it very interesting that the levels of TNF-α secreted from immune cells reported in previous studies22–25 are similar to or lower than those we report with PfTyrRS. A comparison of secreted TNF-α levels (pg ml − 1) is illuminating—using 100 nM PfTyrRS: 1,000–1,300 pg ml − 1, 50–400 nM GPIs; 800–1,300 pg ml − 1, ~µg ml − 1 DNA-protein complexes; 500–600 pg ml − 1 and 30–100 µM hemozoin; 400–600 pg ml − 1, ~500,000 micropar-ticles; 150–200 pg ml − 1. This comparison indicates importance of PfTyrRS as a trigger for excitation of pro-inflammatory cytokine release from host immune cells.

Our corroborative confocal microscopy data not only reveals decoration of host macrophage surfaces with PfTyrRS but also its

20,000a

b

c

15,000

P<0.001

P<0.001

10,000

P<0.01 P<0.01

5,000

0

Geo

met

ric in

tens

ity o

fflu

ores

cenc

e

80,000

60,000

P <0.001

40,000

P<0.01

20,000

0

Geo

met

ric in

tens

ity o

f flu

ores

cenc

e

NS

0.6

0.4

0.5

0.2

0.3

0

0.1

100

Opt

ical

den

sity

obs

erve

d

Protein concentration (nM)

TNF-HUVEC

HUVEC only

PfTyr

RS 3 n

M

PfTyr

RS 6 n

M

PfTyr

RS 12

nM

PfTyr

RS 25

nM

PfTyr

RS 50

nM

HUVEC only

ELR/A

AA 3 n

M

ELR/A

AA 6 n

M

ELR/A

AA 12

nM

ELR/A

AA 25

nM

ELR/A

AA 50

nM

HUVEC

HU+PfT

yrRS

HU+CORL

HU+∅

HU+∅+PfT

yrRS

HU+∅+CORL

TNF-HUVEC

HUVEC

HU+PfT

yrRS

HU+CORL

HU+∅

HU+∅+PfT

yrRS

HU+∅+CORL

03.16.212.52550

Figure 7 | PfTyrRS stimulation of macrophages and subsequent upregulation of endothelial receptors ICAM-1 and VCAM-1. (a) HuVEC cells (Hu) were incubated with PfTyrRs alone, PfDTD (negative control protein (CoRL), macrophage cells (φ) and TnF-α. Culture supernatants of PfTyrRs-induced macrophages and PfDTD-induced macrophages were added to HuVEC cell lines. Expression of ICAm-1 and VCAm-1 was measured by FACs using specific conjugated antibodies. Grey bars (left) represent VCAm-1 expression and black bars (right) represent ICAm-1 expression. (b) PfTyrRs-induced dose-dependent increase in the expression of ICAm-1. no upregulation of ICAm-1 was observed on addition of ELR/AAA PfTyrRs mutant to endothelial cell lines. Bars in black represent PfTyrRs treated samples, whereas bars in grey were the samples treated with ELR/AAA mutant protein (c) mTT cytotoxicity assay with dose-dependent response using PfTyrRs (red line), ELR/AAA mutant (green line), and control (only cells in blue line) on HuVEC cells. no decrease in cell viability was observed (Tukey’s test—P > 0.05). The optical density on y axis in (c) represents cell survival in an mTT assay. Experiments were repeated three times and the error bars represent standard deviation. Tukey’s test was performed and P-values are shown such that the end points of the lines below P-value represent the datasets that were compared. ns, not significant.

ARTICLE

�




internalization. We propose that, as a result of PfTyrRS-macrophage interactions, significantly higher amounts of pro-inflammatory cytokines like TNF-α, IL-1 and IL-6 are released. Elevated cytokine levels can have severe effects in hosts and severe malarial anemia (SMA) provides an excellent example of this45. Increased circulating TNF-α inhibits erythroblast differentiation and dampens erythro-poiesis resulting in worsening SMA symptoms16–21,45. Another outcome of higher levels of circulating TNF-α in infected malaria patients is the increase in expression levels of certain endothelial receptors like ICAM-1, VCAM-1 and E-selectin that contri-bute to cytoadherence in severe malaria39–42. Our data based on co-incubation of three components—purified PfTyrRS macro-phages and endothelial cells, now provides a system that can be further dissected to investigate molecular and cellular interactions that occur during SMA and cytoadherence. This work therefore provides clues to the possibility of PfTyrRS acting as a malarial toxin that can induce cytokine-mediated disease.

Aminoacyl-tRNA synthetases have a vital role in translating the genetic code. Numerous studies have shown that members of this enzyme family are quite adept at ‘moonlighting’ in terms of possess-ing extra capabilities that widen their biological attributes5–8. Studies have indicated that human tyrosyl-, tryptophanyl- and lysyl-tRNA synthetases can be secreted extracellularly and can mimic cytokines5–8. For these extra roles, the human TyrRS and TrpRS require either prote-olytic cleavage or alternate splicing to become active5–9, whereas LysRS can act like a cytokine without processing44. In this light, this is the first report of a human pathogen tRNA synthetase that can also perform moonlighting activity of inducing host immune system to release pro-inflammatory cytokines. In summary, this study suggests that PfTyrRS is secreted from the parasite and deposited proximal to iRBC membrane (despite lack of a ‘PEXEL’ export element43). PfTyrRS egress occurs during trophozoite and schizont stages, before iRBC rupture. On iRBC lysis, PfTyrRS is released into blood plasma, where it is potentially free to interact with host cells. We show that PfTyrRS interacts with specific receptor(s) on host macrophages, and that this event is largely medi-ated by the ELR motif present in PfTyrRS. Finally, we have determined the three-dimensional structure of PfTyrRS in complex with Tyr-AMP, and provide detailed structural comparisons with host counterpart of PfTyrRS. This work therefore not only provides a structural frame-work for using PfTyrRS-YAP complex structure as a starting point for structure-based drug discovery, but also lays foundation for probing key immunological questions in malaria. The twin abilities of malaria parasite tyrosyl-tRNA synthetase—as a housekeeping protein transla-tion enzyme and as a trigger for pro-inflammatory cytokine release in hosts—highlight this protein as a target for discovery of novel anti-parasitic strategies.

MethodsAnimal experiments. Animal experiments were performed in accordance with Institutional Animal Ethics Committee guidelines approved by Department of Biotechnology, Govt of India. This project was approved in a meeting held on 28 October 2009 at ICGEB (approval ID: ICGEB/IAEC/MAL-50). All mice used were killed ethically by asphyxiation in carbon dioxide according to regulatory body instructions.

Synthetic tRNA preparation and aminoacylation assay. Synthetic Plasmodium falciparum tRNA clones were obtained according to Sampson and Uhlenbeck46 by assembling up to 6 oligonucleotides and ligation between HindIII and BamHI sites into pUC19 vector. The tRNAs were obtained by in vitro transcription using T7 RNA polymerase according to standard protocols. In vitro tRNA aminoacyla-tion assays were performed at 37 °C in 50 mM Tris–HCl pH 7.6, 50 mM KCl, 25 mM MgCl2, 5 mM ATP, 0.1 mg ml − 1 BSA, 1 mM DTT, 20 µM tyrosine, 0.5 mCi ml − 1 l–[3,5-3H]tyrosine and 0.5 µM PfTyrRS as reported47. Reaction was initi-ated by addition of pure enzyme and samples of 20 µl were spotted onto Whatman 3 mM discs at varying time intervals (usually 2 min). Radioactivity (corresponding to amino acid ligated to tRNA substrate) was measured by liquid scintillation.

Protein expression, purification and crystallization. TyrRS gene (MAL8P1.125). from P. falciparum was PCR amplified from complementary DNA and cloned

into pQE30 vector (Qiagen). Four hours post -IPTG (isopropyl 1-thio-d- galactopyranoside, 0.5 mM) induction, the bacterial cell pellet was suspended in buffer containing 50 mM Tris–HCl, 500 mM NaCl, 50 mM imidazole, pH 8.0 and protease inhibitor cocktail. Protein was purified using Ni-NTA beads (Qiagen) and gel filtration chromatography. Pure, dimeric PfTyrRS was concentrated and buffer exchanged into 25 mM Tris–HCl pH 8.0, 150 mM NaCl and 10 mM BME. Dif-fraction quality crystals using His-tag-free PfTyrRS were grown by hanging drop vapour diffusion method at 20 °C. The droplet size was 1 µl of protein (30 mg ml − 1 in 25 mM Tris pH 8.0, 100 mM NaCl, 10 mM BME, 10 mM MgCl2, 10 mM ATP and 2 mM l–tyrosine) with 1 µl of reservoir solution equilibrated over 200 µl of 2.4 M sodium malonate at pH 6.0.

Data collection and structure determination. A single crystal was transferred to cryoprotectant reagent (paratone oil) for a short period (5–10 s) before freezing in a stream of cooled nitrogen gas. Data were collected at 100 K using Cu Kα radiation (λ = 1.54 Å) on a MAR345 image-plate detector mounted on a Rigaku MicroMax-007 rotating-anode X-ray generator. A total of 700 frames were collected in 1° oscillation steps with 5 min exposure per frame, and data were processed with HKL2000 (ref. 48). The structure was solved by molecular replacement in MOL-REP49 using cytoplasmic mini-HsTyrRS (PDB: 1N3L) as a starting model. Iterated manual model building and refinement was done using COOT50 and phenix.refine51. The structural representations in this paper were prepared with Chimera52 and PyMOL (http://www.pymol.org).

Cell-binding assays. For in vitro localization experiments, synchronous parasite cultures of P. falciparum 3D7 were washed with PBS, fixed in solution using 4% paraformaldehyde and 0.0075% glutraldehyde for 20 min, permeablized with 0.1% Triton X-100 for 10 min and then treated for 10 min with 0.1 mg ml − 1 sodium borohydride in PBS. Each step was followed by a brief PBS wash53. Cells were blocked in 3% BSA, PBS for 1 h, washed in PBS and incubated overnight with protein-A column purified rabbit anti-PfTyrRS antibodies (1:150 dilution in PBS containing 3% BSA) at 4 °C. After three washes (10 min each) with PBS, the cells were incubated with Alexa Fluor488-conjugated anti-rabbit secondary antibody (1:250 dilution in PBS containing 3% BSA) for 2 h at room temperature and allowed to settle onto poly-d-lysine (100 mg ml − 1)-coated coverslips. These were then washed three times in PBS and mounted in antifade with DAPI (Molecular Probes). Spleen cells were purified from P. yoelii-infected mice and PBMCs were isolated from both mouse and human blood as described earlier54. For the in vivo experiment, C57BL/6 mice were infected with ~1 million P. yoelii (17XNL strain) in the form of parasitized RBC’s intraperitoneally. Fifteen days after infection, the spleens were collected from infected and age-and-sex matched uninfected control mice. Spleens were crushed and lymphocytes were isolated and stained for flow cytometry by standard procedures. The cells were fixed with Cytofix (BD Biosciences) and permeabilized with 1X Cytoperm (BD Biosciences) for intracellular TyrRS staining. The data was acquired on BD FACS Canto II (BD Biosciences) and analysed on by FlowJo software (Treestar). Human PBMCs were isolated using BD Vacutainer CPT tubes (BD Biosciences) by centrifugation at 1,600 g per 25 min/RT/no brake. The cells were thoroughly washed and resuspended in complete RPMI containing 10% FCS in a 24-well plate, and 100 nM purified PfTyrRS protein was added for 3 h at 37 °C (95% humidity, 5% CO2). Analytical flow cytometry was performed by direct staining for specific popula-tions of immune cells with fluorescently conjugated antibodies and biotin- conjugated anti-PfTyrRS antibody (1:150 dilution in PBS). The data obtained on BD FACS Canto II (BD Biosciences) was analysed using FlowJo software (Treestar). In vitro binding of PfTyrRS to various immune cells was performed by FACS using standard protocols. Dendritic cells and macrophage ThP1 cells were cultured on coverslips in 24-well plates (Gibson) and maintained in DMEM medium containing 20% (v/v) FBS and 1% antibiotics (Gibco). PfTyrRS and other control proteins were incubated with cells at several concentrations for 5 min to 2 h at 4 °C. Cells were washed twice in PBS and incubated with 2% formaldehyde (Sigma) for 15 min and followed by incubation for 10 min with 0.1% saponin (Sigma). Primary and secondary antibodies were added as per manufacturer’s instructions (Molecular Probes). Fluorescence microscopy was performed on Nikon A1R confocal laser scanning microscope.

Western blots. P. falciparum (schizont stage) -infected human erythrocytes (1.5×107 parasites per ml) were enriched and parasites were cultured for 6–10 h to allow the maturation of schizonts, release of merozoites and their material54. Culture supernatant was collected in the presence of protease inhibitor cocktail after two rounds of centrifugation of 1,000 g for 15 min followed by 10,000 g for 20 min before freezing at − 70 °C. Culture supernatant was subsequently used for western blotting using different antibodies against PfDTD (dilution, 1:500), Pf falcipain 2 (dilution, (1:1,000), PfMSP-1 (dilution, 1:1,000) and PfTyrRS (dilution, 1:500).

Cytokine secretion assays. Raw-264.7. cells, J774 murine cells, Dendritic cells (isolated from femur bone marrow of the mice C57BL/6) and human THP1 macrophage cells (3×104) were cultured in RPMI medium with 10% FBS and 1% antibiotics in 24-well format plates. Proteins were passed through polymyxin

ARTICLE

�0�




beads (Sigma) before assays. LPS, PfTyrRS and control proteins were added to the medium at different concentrations. 100 µl of culture medium was collected and centrifuged after every 4, 24 and 48 h. Cytokines in the culture supernatant were detected by a Luminex microbead-based multiplexed assay (Bio-Plex manager 5.0) using commercially available kits according to the manufacturer’s protocol (Bio-Plex, Bio-Rad). All proteins were tested for endotoxin contaminations and passed through polymyxin beads (Sigma). LAL (Limulus Amebocyte Lysate) assay was performed to confirm that the proteins were endotoxin-free before each assay.

PfTyrRS interaction with human macrophages. Cultured human macrophages cells were mixed with PfTyrRS in absence or presence of different antibodies, namely anti-PfTyrRS, anti-CXCR1 and anti-CXCR2. Binding of PfTyrRS was tested using standard FACS protocols. In related experiments, cytokine profiling of these human macrophages was also done, either in absence or presence of antibodies used above. Cytokines released in culture supernatants were detected by a Luminex microbead-based multiplexed assay (Bio-Plex manager 5.0) using commercially available kits and according to the manufacturer’s protocol (Bio-Plex, Bio-Rad). Similar experiments were performed using various wild-type and mutant ELR-based peptides. Human macrophages (ThP1 cells) were incubated with 100 nM of these peptides before addition of PfTyrRS. FACS and cytokine profiling were again done on all these samples as for the antibody treatment experiments.

Upregulation of endothelial cell receptors. Monocytes were obtained from buffy coat by Lymphoprep (Axis-Shield) gradient centrifugation, followed by adhesion-mediated purification on tissue culture plastic. The cells were cultured for 3 days in RPMI-164 medium (Sigma) supplemented with 2 mM l-glutamine and 10% FBS to differentiate into macrophage. The recombinant PfTyrRS or control pro-teins were added at a concentration of 1 µl ml − 1 on day 3, and cells were cultured continuously for 3 days. The culture supernatant was collected and centrifuged at 13,000 g for 10 min to remove any debris; the supernatant was used for co-culture with endothelium. Primary pooled human umbilical vein endothelial cells (HUVEC) were obtained from Promocell). Cells were maintained in complete growth medium supplied by Promocell, according to the company’s instructions. To reduce variation, only cells at passage five to six were used. HUVEC were grown on 1% gelatin (Sigma) coated on 24-well plates with appropriate growth medium, until confluent. Then, the culture medium was replaced with either fresh medium alone, medium containing recombinant PfTyrRS or control protein (added at concentration 100 nM) or macrophage culture supernatants. These were incubated at 37 °C in 5% CO2 for 16 h. Endothelial cell markers were measured by fluores-cence-activated cell sorting (FACScan; Becton Dickinson). Specific fluorescence-conjugated antibodies, including APC Mouse anti-human CD54 (ICAM-1) and PE Mouse anti-human CD106 (VCAM-1) (Becton Dickinson), were used in this study. Nonspecific fluorescence was assessed using corresponding isotype control antibodies. The expression of endothelial surface proteins ICAM-1 and VCAM-1 was indicated by geometric mean of the fluorescence intensity. PfTyrRS was subsequently used in a dose-dependent experiment for testing increased expression of ICAM-1, using the protocols described above.

PfTyrRS-GFP microscopy. The gene was amplified with genomic DNA of P. falciparum using following primers: forward-5′-CTCGAGATGATAATAT TAAAGGTTTTATTTA-3′ reverse-5′-GGTACCTTTTATTATTATAGAATAAC TTGTTC-3′ and cloned into pGEM-T vector (Promega). The insert was released from pGEMT and cloned between XhoI and KpnI in pGlux vector (Amersham). Transformations and clone propagation was done in Dh5α cells. Transfection of vectors into the parasite was done, as described earlier55. GFP-expressing infected erythrocytes were studied live or fixed at ambient temperature. Cells were viewed with a UPlanSApo ×100 1.4 oil objective on a Olympus IX81 Live Cell Imaging Inverted Microscope equipped with an Olympus F-View camera and primarily processed with analySIS LS Research software package. Captured images were then further processed using Photoshop and ImageJ. Pictures were adjusted to gain optimal contrast to visualize features of interest.

MTT assays. HUVEC cells at passage 5 were seeded at a concentration of 2×104 cells per well (in 100 µl) and allowed to attach for 24 h on 1% gelatine (Sigma) coated on 96-well plates in complete growth medium under standard conditions (5% CO2, 95% humidity, 37 °C). Then, the cells were exposed to PfTyrRS at the concentrations indicated along with mutant PfTyrRS or HUVEC alone. The exposure time was 24 hours. Afterwards, the cell culture medium was withdrawn and in each well 10 µl MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, Sigma] stock solution (5 mg ml − 1) was added, followed by an incubation period of 4 h. Afterwards, 100 µl per well stop solution (40 g SDS per 200 ml 50% DMF (NN-Dimethyformide, Sigma)) was added, followed by an incubation step overnight (37 °C). MTT metabolization as parameter for metabolic activity was recorded spectrophotometrically by Varioskan at 570 nm.

Statistical analyses. Data are derived from multiple independent experiments done in triplicates. Statistical analyses were conducted using SPSS software and values are presented as mean ± s.d. Significant differences between groups were determined by ANOVA followed by Tukey’s multiple comparison test (SPSS software). A value of P < 0.05 was accepted as an indication of statistical significance.

References1. Ibba, M. & Söll, D. Aminoacyl-tRNA synthesis. Annu. Rev. Biochem. 69,

617–650 (2000).2. Ibba, M. & Söll, D. The renaissance of aminoacyl-tRNA synthesis. EMBO Rep.

2, 382–387 (2001).3. Eriani, G., Delarue, M., Poch, O., Gangloff, J. & Moras, D. Partition of tRNA

synthetases into two classes based on mutually exclusive sets of sequence motifs. Nature 347, 203–206 (1990).

4. Burbaum, J. J. & Schimmel, P. Structural relationships and the classification of aminoacyl-tRNA synthetases. J. Biol. Chem. 266, 16965–16968 (1991).

5. Brown, M. V., Reader, J. S. & Tzima, E. Mammalian aminoacyl-tRNA synthetases: cell signaling functions of the protein translation machinery. Vascul. Pharmacol. 52, 21–26 (2010).

6. Bhatt, T. K. et al. A genomic glimpse of aminoacyl-tRNA synthetases in malaria parasite Plasmodium falciparum. BMC Genomics 10, 644 (2009).

7. Guo, M., Yang, X. L. & Schimmel, P. New functions of aminoacyl-tRNA synthetases beyond translation. Nat. Rev. Mol. Cell Biol. 11, 668–674 (2010).

8. Guo, M., Schimmel, P. & Yang, X. L. Functional expansion of human tRNA synthetases achieved by structural inventions. FEBS Lett. 584, 434–442 (2010).

9. Wakasugi, K. & Schimmel, P. Two distinct cytokines released from a human aminoacyl-tRNA synthetase. Science 284, 147–151 (1999).

10. Wakasugi, K., Slike, B. M., Hood, J., Ewalt, K. L., Cheresh, D. A. & Schimmel, P. Induction of angiogenesis by a fragment of human tyrosyl-tRNA synthetase. J. Biol. Chem. 277, 20124–20126 (2002).

11. Yang, X. L. et al. Gain-of-function mutational activation of human tRNA synthetase procytokine. Chem. Biol. 14, 1323–1333 (2007).

12. Kapoor, M., Otero, F. J., Slike, B. M., Ewalt, K. L. & Yang, X. L. Mutational separation of aminoacylation and cytokine activities of human tyrosyl-tRNA synthetase. Chem. Biol. 16, 531–539 (2009).

13. Yang, X. L., Skene, R. J., McRee, D. E. & Schimmel, P. Crystal structure of a human aminoacyl-tRNA synthetase cytokine. Proc. Natl Acad. Sci. USA 99, 15369–15374 (2002).

14. World Health Organization (2009) WHO World malaria report, http://www.who.int/malaria/world_malaria_report_2009/en/index.html.

15. Milner, D. A. Jr. Rethinking cerebral malaria pathology. Curr. Opin. Infect. Dis. 23, 456–463 (2010).

16. Clark, I. A., Budd, A. C., Alleva, L. M. & Cowden, W. B. Human malarial disease: a consequence of inflammatory cytokine release. Malaria J. 5, 85 (2006).

17. Riley, E. M., Wahl, S., Perkins, D. J. & Schofield, L. Regulating immunity to malaria. Parasite Immunol. 28, 35–49 (2006).

18. Corrigan, R. A. & Rowe, J. A. Strain variation in early innate cytokine induction by Plasmodium falciparum. Parasite Immunol. 32, 512–527 (2010).

19. Robinson, L. J. et al. Cellular tumor necrosis factor, gamma interferon, and interleukin-6 responses as correlates of immunity and risk of clinical Plasmodium falciparum malaria in children from Papua New Guinea. Infect. Immun. 77, 3033–3043 (2009).

20. Dodoo, D., Omer, F. M., Todd, J., Akanmori, B. D., Koram, K. A. & Riley, E. M. Absolute levels and ratios of proinflammatory and anti-inflammatory cytokine production in vitro predict clinical immunity to Plasmodium falciparum malaria. J. Infect. Dis. 185, 971–979 (2002).

21. Brustoski, K. et al. IFN-γ and IL-10 mediate parasite-specific immune responses of cord blood cells induced by pregnancy-associated Plasmodium falciparum malaria. J. Immunol. 174, 1738–1745 (2005).

22. Coban, C. et al. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J. Exp. Med. 201, 19–25 (2005).

23. Krishnegowda, G. et al. Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity. J. Biol. Chem. 280, 8606–8616 (2005).

24. Couper, K. N. et al. Parasite-derived plasma microparticles contribute significantly to malaria infection-induced inflammation through potent macrophage stimulation. PLoS Pathog. 6, e1000744 (2010).

25. Wu, X., Gowda, N. M., Kumar, S. & Gowda, D. C. Protein-DNA complex is the exclusive malaria parasite component that activates dendritic cells and triggers innate immune responses. J. Immunol. 184, 4338–4348 (2010).

26. Fechter, P., Rudinger-Thirion, J., Théobald-Dietrich, A. & Giegé, R. Identity of tRNA for yeast tyrosyl-tRNA synthetase: tyrosylation is more sensitive to identity nucleotides than to structural features. Biochemistry 39, 1725–1733 (2000).

27. Quinn, C. L., Tao, N. & Schimmel, P. Species-specific microhelix aminoacylation by a eukaryotic pathogen tRNA synthetase dependent on a single base pair. Biochemistry 34, 12489–12495 (1995).

28. Tsunoda, M. et al. Structural basis for recognition of cognate tRNA by tyrosyl-tRNA synthetase from three kingdoms. Nucleic Acids Res. 35, 289–4300 (2007).

ARTICLE

��




29. Bonnefond, L. et al. Crystal structure of human mitochondrial tyrosyl-tRNA synthetase reveals common and idiosyncratic features. Structure 15, 1505–1516 (2007).

30. Zhao, X., Town, J. R., Li, F., Zhang, X., Cockcroft, D. W. & Gordon, J. R. ELR-CXC chemokine receptor antagonism targets inflammatory responses at multiple levels. J. Immunol. 182, 3213–3222 (2009).

31. Gamo, F. J. et al. Thousands of chemical starting points for antimalarial lead identification. Nature 465, 305–310 (2010).

32. Bhatt, T. K., Yogavel, M., Wydau, S., Berwal, R. & Sharma, A. Ligand-bound structures provide atomic snapshots for the catalytic mechanism of D-amino acid deacylase. J. Biol. Chem. 285, 5917–5930 (2010).

33. Yogavel, M., Khan, S., Bhatt, T. K. & Sharma, A. Structure of D-tyrosyl-tRNATyr deacylase using home-source Cu Kα and moderate-quality iodide-SAD data: structural polymorphism and HEPES-bound enzyme states. Acta Crystallogr. D Biol. Crystallogr. 66, 584–592 (2010).

34. López, J. A. Malignant malaria and microangiopathies: merging mechanisms. Blood 115, 1317–1318 (2010).

35. Medana, I. M. & Turner, G. D. Human cerebral malaria and the blood-brain barrier. Int. J. Parasitol. 36, 555–568 (2006).

36. Wilson, N. O. et al. Soluble factors from Plasmodium falciparum-infected erythrocytes induce apoptosis in human brain vascular endothelial and neuroglia cells. Mol. Biochem. Parasitol. 162, 172–176 (2008).

37. Combes, V., Coltel, N., Faille, D., Wassmer, S. C. & Grau, G. E. Cerebral malaria: role of microparticles and platelets in alterations of the blood-brain barrier. Int. J. Parasitol. 36, 541–546 (2006).

38. Pasternak, N. D. & Dzikowski, R. PfEMP1: an antigen that plays a key role in the pathogenicity and immune evasion of the malaria parasite Plasmodium falciparum. Int. J. Biochem. Cell Biol. 41, 14631466 (2009).

39. Tripathi, A. K., Sha, W., Shulaev, V., Stins, M. F. & Sullivan, D. J. Jr. Plasmodium falciparum-infected erythrocytes induce NF-kappaB regulated inflammatory pathways in human cerebral endothelium. Blood 114, 4243–4252 (2009).

40. Stevenson, M. M. & Urban, B. C. Antigen presentation and dendritic cell biology in malaria. Parasite Immunol. 28, 5–14 (2006).

41. Diouf, I. et al. IL-12 producing monocytes and IFN-gamma and TNF-alpha producing T-lymphocytes are increased in placentas infected by Plasmodium falciparum. J. Reprod. Immunol. 74, 152–162 (2007).

42. Francischetti, I. M., Seydel, K. B. & Monteiro, R. Q. Blood coagulation, inflammation, and malaria. Microcirculation 15, 81–107 (2008).

43. Goldberg, D. E. & Cowman, A. F. Moving in and renovating: exporting proteins from Plasmodium into host erythrocytes. Nat. Rev. Microbiol. 8, 617–621 (2010).

44. Park, S. G. et al. Human lysyl-tRNA synthetase is secreted to trigger proinflammatory response. Proc. Natl Acad. Sci. USA 102, 6356–6361 (2005).

45. Haldar, K. & Mohandas, N. Malaria, erythrocytic infection, and anemia. Hematology Am. Soc. Hematol. Educ. Program 87–93 (2009).

46. Sampson, J. R. & Uhlenbeck, O. C. Biochemical and physical characterization of an unmodified yeast phenylalanine transfer RNA transcribed in vitro. Proc. Natl Acad. Sci. USA 85, 1033–1037 (1988).

47. Schulman, L. H. & Pelka, H. Anticodon loop size and sequence requirements for recognition of formylmethionine tRNA by methionyl-tRNA synthetase. Proc. Natl Acad. Sci. USA 80, 6755–6759 (1983).

48. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307–326 (1997).

49. Vagin, A. & Teplyakov, A. Molecular replacement with MOLREP. Acta Crystallogr. D Biol. Crystallogr. 66, 22–25 (2010).

50. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132 (2004).

51. Adams, P. D. et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D Biol. Crystallogr. 58, 1948–1954 (2002).

52. Pettersen, E. F. et al. UCSF Chimera--a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).

53. Tonkin, C. J. et al. Localization of organellar proteins in Plasmodium falciparum using a novel set of transfection vectors and a new immunofluorescence fixation method. Mol. Biochem. Parasitol. 137, 13–21 (2004).

54. Haynes, J. D. et al. Receptor-like specificity of a Plasmodium knowlesi malarial protein that binds to Duffy antigen ligands on erythrocytes. J. Exp. Med. 167, 1873–1881 (1988).

55. Crabb, B. S. et al. Transfection of the human malaria parasite Plasmodium falciparum. Methods Mol. Biol. 270, 263–276 (2004).

AcknowledgementsWe thank Monika Chugh for help with western blotting of culture supernatants. T.K.B., S.K., M.M.B. and A.S. are supported by Department of Biotechnology and CSIR fellowships. A.G.M. is an ARC Australian Research Fellow. This work in part was conducted under EU MEPHITIS project (Grant Agreement no: HEALTH-F3-2009-223024). Funding for research on malaria tRNA synthetases is provided by a DBT grant to the laboratory.

Author contributionsT.K.B., S.K., V.D. and M.Y. carried out protein studies, collected localization data, and performed structural analyses along with immunological experiments. T.K.B., S.K., M.Y., A.C. and A.S. analysed all data and wrote the manuscript. M.M.B. performed cloning, purified PfTyrRS and crystallized it. A.S. and A.C. helped with cell biology experiments. N.C. and R.P.L. performed aminoacylation assays. Y.W. and A.G.C. performed endothelial activation assays. A.G.M. and A.T.M. performed PfTyrRS-GFP microscopy.

Additional informationAcccession codes: Coordinates and structure factors for PfTyrRS have been deposited in the RCSB Protein Data Bank under accession code 3vgj.

Supplementary Information accompanies this paper at http://www.nature.com/naturecommunications

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

How to cite this article: Bhatt, T. K. et al. Malaria parasite tyrosyl-tRNA synthetase secretion triggers pro-inflammatory responses. Nat. Commun. 2:530 doi: 10.1038/1522 (2011).

malaria parasite tyrosyl-trna synthetase secretion ... › bitstream › 1885 › 5217… · tarun...

Documents